Offbeat Trading Idea MorphoSys: Is that the spark?

13:25  28 october  2020
13:25  28 october  2020 Source:   finanzen.net

technology breakdown paralyzes trading on the Euronext multi-country exchange

 technology breakdown paralyzes trading on the Euronext multi-country exchange London (Reuters) - Trading on the Euronext multi-country exchange came to a complete standstill on Monday. © Reuters / CHARLES PLATIAU Logo of Euronext is seen on the headquarters at La Defense business and financial district in Courbevoie near Paris Reason are technical problems, the group announced. Euronext is working on a solution. Share trading in Paris, Amsterdam, Brussels and Lisbon, among others, is affected.

MorphoSys AG has a current ratio of 5.3, demonstrating that it is liquid and is capable to disburse its financial MorphoSys operates under Biotechnology classification in the United States and is traded on What is your trading attitude regarding investing in MorphoSys AG? Are you bullish or bearish?

MorphoSys AG is a biopharmaceutical company founded in 1992. The company is headquartered near Munich, Germany and has a wholly owned subsidiary, MorphoSys US Inc., in Boston MA in the US, where it is building a commercial organization.

The biotech company MorphoSys has taken the market by surprise. With the preliminary figures for the first nine months, the company, which specializes in the therapeutic use of antibodies, has significantly raised its outlook for the full year.

DANIEL ROLAND/AFP/Getty Images © Provided by Finanz.net DANIEL ROLAND / AFP / Getty Images

Accordingly, MorphoSys now expects annual sales of EUR 317 to 327 million. The previous forecast range was between 280 and 290 million euros. People are also more optimistic about yield. The result before interest and taxes should now be between 10 and 20 million euros. The previous forecast was based on a range that ranged from a maximum loss of 15 million euros to a profit of 5 million euros.

UK limit on cryptocurrency derivatives draws attention in US

  UK limit on cryptocurrency derivatives draws attention in US The U.K.’s decision this month to limit retail access to financial derivatives linked to cryptocurrencies caught the eye of legal experts in the U.S. and is fueling debate about whether Washington could follow the move in London, especially if Democrat Joe Biden wins the presidency. Robert Hockett, a professor at Cornell Law School, may be an […] The post UK limit on cryptocurrency derivatives draws attention in US appeared first on Roll Call.

Get today's Morphosys AG O.N. stock price and latest MORG news as well as Morphosys AG real-time stock quotes, technical analysis, full financials This is the main Morphosys AG O.N. stock chart and current price. You can find more details by going to one of the sections under this page such as

MorphoSys (FSE & NASDAQ: MOR) is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of exceptional, innovative therapies for patients suffering from serious diseases. The focus is on cancer. Based on its leading expertise in antibody

These are, of course, substantial improvements in the outlook, and that has spurred the stock on in the short term. The stock was recently in a correction trend and broke down through the 200-day line a good month ago. Now the new forecasts could herald a new trend reversal, even if the share has to give up the latest price gains again today in a very weak overall market.

From the current basis, a potential for recovery up to the 200-day line is conceivable, that would be around 20 percent. This is certainly still a very speculative approach, as the indications for a short-term bottoming out are there, but still thin. Nevertheless, it could be extremely lucrative here to accompany this with a leverage product.

would offer a mini long from Citi with a leverage of currently 4.5. Based on the estimate of the potential in the underlying up to the 200-day line, we would trust the certificate to achieve a possible performance of around 90 percent, the price target would be EUR 3.60. A stop loss is available at 1.10 euros.

• Underlying: MorphoSys

• Product type: Knock-out Warrants

• Issuer: Citi

• ISIN: DE000KB1G6C7

• Term: Open end

• Price knockout call (28.10.20, 11:11 a.m. ): 1.91 euros

• Base price variable: 67.3702 euros

• Knock-out threshold: 71.20 euros

• Lever: 4.5

• Distance to knock-out: 17.5 percent

• Stop- Loss call: 1.10 euros

Patriots unlikely to trade reigning DPOY Stephon Gilmore? .
In addition to the high-level draft picks that a Gilmore trade would entail, the acquiring team must also be prepared to pony up a massive extension soon. Gilmore’s contract runs through the 2021 campaign, and even though he is not performing at the same level this year as he was in 2019, he will surely demand a top-of-the-market contract this offseason.Subscribe to Yardbarker's Morning Bark, the most comprehensive newsletter in sports. Customize your email to get the latest news on your favorite sports, teams and schools. Emailed daily.

usr: 1
This is interesting!